Ascendis Pharma Posts Robust Q4 Growth and Details Phase 3 CNP Trial
Ascendis Pharma posted robust Q4 2025 revenue growth driven by its TransCon PTH and hGH franchises and maintained its full-year 2025 guidance. Management outlined strategic pipeline progress with initiation of the Phase 3 TransCon CNP trial and cost-control measures targeting profitability in 2026.
1. Q4 Revenue Performance
Ascendis Pharma delivered year-over-year Q4 revenue growth led by strong uptake of its TransCon PTH and TransCon hGH products, and management affirmed its full-year 2025 revenue guidance without adjustment.
2. Pipeline and Strategic Initiatives
During the call, leadership highlighted the initiation of the Phase 3 trial for TransCon CNP in achondroplasia, discussed timelines for upcoming clinical readouts and outlined cost-control measures intended to drive the company toward profitability by 2026.